Vulvar adenocarcinoma

Summary

Vulvar adenocarcinoma (MONDO:0024336) is a disease (an umbrella term covering 7 Mondo subtypes) and 3 clinical trials. Top therapeutic interventions include tremelimumab. A subtype of vulvar glandular neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvar adenocarcinoma
Mondo ID	MONDO:0024336
Orphanet	494454
DOID	DOID:2098
NCIT	C6380
UMLS	C1336975
MedGen	234480
GARD	0022007
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	no

Also known as: adenocarcinoma of the vulva · adenocarcinoma of vulva · mammalian vulva adenocarcinoma · vulva adenocarcinoma · vulvar adenocarcinoma

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vulvar disease › vulvar neoplasm › vulvar glandular neoplasm › vulvar adenocarcinoma

Related subtypes (3): minor vestibular glands adenoma, Bartholin gland adenoma, Bartholin gland adenomyoma

Subtypes (7): vulval Paget disease, vulvar sebaceous carcinoma, Bartholin gland adenocarcinoma, vulvar eccrine adenocarcinoma, vulvar apocrine adenocarcinoma, adenocarcinoma of skene gland origin, vulvar clear cell hidradenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07454642	PHASE1	RECRUITING	AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT03452332	PHASE1	COMPLETED	Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
NCT02140021	Not specified	TERMINATED	Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TREMELIMUMAB	4	1